All News

Patients with multiple sclerosis (MS) may not have an increased risk of contracting coronavirus disease 2019 (COVID-19), explained John Corboy, MD, of the University of Colorado Denver, School of Medicine.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Authors in the Journal of Clinical Oncology discuss hypotheses on the differences in mutations and implications for treatment with PARP inhibitors.

In the FIDELIO-DKD trial researchers purposely recruited centers that had very large African American databases, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.

More than 1 in 4 patients with COVID-19 admitted to the hospital during the first wave of the pandemic in Finland were found to have obstructive sleep apnea, signaling a potential at-risk population.

Using DIXON, T2 mapping, and diffusion tensor imaging, the researchers obtained quantitative MRI for 31 patients with spinal muscular atrophy (SMA) types 2 and 3.

Patients with chronic obstructive pulmonary disease (COPD) may experience a difference in symptom severity depending on which risk factors they are exposed to across their lifetime.

Mounting evidence is supporting the use of poly ADP-ribose polymerase (PARP) inhibitors in prostate cancer, according to a new study.

The shift to treat patients with pediatric-onset multiple sclerosis (POMS) who are treated earlier with a wider variety of medications has led to better outcomes, according to a recent study.

Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.

Pfizer will submit an emergency use authorization for their coronavirus disease 2019 (COVID-19) vaccine; WHO panel recommends against remdesivir; CDC urges Americans to stay put during Thanksgiving.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

This week, the top managed care news included reports of 2 vaccines’ efficacy against coronavirus disease 2019 (COVID-19); a study finds no risk reduction in cardiac events with fish oil; calls for long-term follow-up to understand effects of lingering COVID-19.

A study looked at how 4 types of interventions for children with asthma could impact expenditures and utilization among Medicaid programs.

The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.

In addition to different dosage forms of levodopa—the current standard of care for Parkinson disease—emerging trials are also examining alpha-synuclein, an abnormal protein that may be involved in the pathogenesis of the condition.

A new analysis of CREDENCE data showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor worked in advanced disease and without causing acute kidney injury.

Patients younger than 65 years represent close to 40% of deaths from metastatic breast cancer, yet their use of end-of-life (EOL) care has not been thoroughly investigated until now.

Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.

The authors of a Commentary in the November 2020 issue of The American Journal of Managed Care describe the experience of reimagining how a home health program can deliver care amid the coronavirus disease 2019 pandemic.

AstraZeneca data show the company's coronavirus disease 2019 vaccine had promising results in older adults; nurses implore the public to take virus safety precautions; a new report highlights employees on food stamps, Medicaid.

At its annual meeting, the American College of Rheumatology previewed updates to guidelines for the management of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).

The treatment combination demonstrated an overall response rate of 44% and median overall survival of 9.5 months.

Women filling a prescription for female hormone therapy (FHT), and presumably taking FHT, are not at increased risk of retinal artery or retinal vein occlusions.

Following 6 injections of nusinersen, respiratory muscle performance was significantly better among the treated patients compared with age‐matched historical controls.

Results from a phase 3 study of Xywav in adult patients with idiopathic hypersomnia exhibited its potential to address this unmet medical need.

Severe pulmonary arterial hypertension (PAH) was associated with a significantly higher rate of maternal and fetal mortality.

While patients with severe chronic obstructive pulmonary disease (COPD) are receiving referrals for pulmonary rehabilitation (PR), female patients and other groups are less likely to receive them.